Company Update

Concord Drugs Limited has submitted its Annual Secretarial Compliance Report for the year ended March 31, 2025, prepared by PSK & Associates, confirming adherence to applicable SEBI regulations and corporate governance practices.

The report notes a minor delay in filing under Regulation 76 of Depositories and Participants Regulations, with management assuring more careful compliance going forward.

No other regulatory deviations, director disqualifications, or related party transaction issues were observed.

The company maintains its website and policies per guidelines, conducts regular board and committee performance evaluations, and complies with insider trading norms.

No actions were taken by SEBI or stock exchanges against the company or its directors.